Editorial Comments

1 The Demise of Bazett’s Formula?
Bamimore, A.; Budzikowski, A.S. (Brooklyn, N.Y.)

20 The Human Story of Aortic Stenosis: A Time for New Surrogate Markers in Clinical Decision Making
Dell’Italia, L. (Birmingham, Ala.)

Original Research

3 Predicting Torsade de Pointes in Acquired Long QT Syndrome: Optimal Identification of Critical QT Interval Prolongation

12 Frequency, Risk Factors and Prognosis of Postoperative Hyperbilirubinemia after Heart Valve Surgery

36 Expression of MicroRNA-1 and MicroRNA-21 in Different Protocols of Ischemic Conditioning in an Isolated Rat Heart Model

44 Holter Monitoring and Long-Term Prognosis in Hypertrophic Cardiomyopathy

Turning Basic Research into Clinical Success

23 Inflammatory Cytokines in Heart Failure: Mediators and Markers

55 Characterization of the Role of Nitric Oxide and Its Clinical Applications
Levine, A.B.; Punihaole, D.; Levine, T.B. (Pittsburgh, Pa.)
A complete guide to progress in thoracic medicine

Respiration

Official Journal of the European Association for Bronchology and Interventional Pulmonology (EAB) and the Swiss Society for Pneumology (SGP)

Impact Factor: 2.543

More information at www.karger.com/res

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription
- Free Alert Service
- Online Library Recommendation

Selected contributions

Polymorphisms of Hypoxia-Related Genes in Subjects Susceptible to Acute Mountain Sickness: Ding, H.; Liu, Q.; Hua, M.; Ding, M.; Du, H.; Zhang, W.; Li, Z.; Zhang, J. (Beijing)

Impact of a Rehabilitation Program on Dyspnea Intensity and Quality in Patients with Chronic Obstructive Pulmonary Disease: Bianchi, R.; Gigliotti, F.; Romagnoli, J.; Lanini, B.; Castellani, C.; Binazzi, B.; Stendardi, L.; Bruni, G.J.; Scano, G. (Pozzolatico)

Exposure to Secondhand Tobacco Smoke Enhances Respiratory Symptoms and Responses to Animals in 8,819 Children in Kindergarten: Results from 25 Districts in Northeast China: Dong, G.-H.; Ren, W.-H.; Wang, D.; Yang, Z.-H.; Zhang, F.-F.; Zhao, Y.-D.; He, Q.-C. (Shenyang)

Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights: Adcock, I.M. (London); Caramori, G. (Ferrarra); Barnes, P.J. (London)

Estimating Peak Work Rate during Incremental Cycle Ergometry from the 6-Minute Walk Distance: Differences between Reference Equations: Holland, A.E. (Melbourne, Vic.); Hill, K. (Perth, W.A.); Alison, J.A.; Luxton, N.; Mackey, M.G. (Sydney, N.S.W.); Hill, C.J. (Melbourne, Vic.); Jenkins, S.C. (Perth, W.A.)


CARDIOLOGY

International Journal of Cardiovascular Medicine, Surgery, Pathology and Pharmacology


Incorporating Heart Drug (published 2001–2005)

Editor-in-Chief
Jeffrey S. Borer, New York, N.Y.

Associate Editors
D. Atar, Oslo
H. Boudoulas, Athens
J.A. Franciosa, New York, N.Y.
I.J. Gelb, Boca Raton, Fla.
J.T. Kassotis, Brooklyn, N.Y.
W. Ko, New York, N.Y.
B.S. Lewis, Haifa
D.J. Sahn, Portland, Oreg.
S. Sasayama, Kyoto
J. Somberg, Chicago, Ill.
H. Taegtmeyer, Houston, Tex.

Editorial Board
E. Abadie, Saint Denis
D.H. Adams, New York, N.Y.
C.W. Akins, Boston, Mass.
J.S. Alpert, Tucson, Ariz.
E.A. Amsterdam, Davis, Calif.
J.J. Badimon, New York, N.Y.
A. Battler, Pehah Tikva
J. Bax, Leiden
R.C. Becker, Durham, N.C.
G.A. Beller, Charlotteville, Va.
P.C. Block, Atlanta, Ga.
R.O. Bonow, Chicago, Ill.
A.S. Budzikowski, Brooklyn, N.Y.
A.J. Camm, London
B.A. Carabello, Houston, Tex.
K. Chatterjee, Iowa City, I.A.
P.F. Cohn, Stony Brook, N.Y.
J. Coromilas, New Brunswick, N.J.
M.H. Crawford, San Francisco, Calif.
J.E. Dalen, Tucson, Ariz.
S. Dalla Volta, Padova
P.C. Deedwania, Fresno, Calif.
A.N. De Maria, San Diego, Calif.
J.A. Elefteriades, New Haven, Conn.
U. Elkayam, Los Angeles, Calif.
C. Erol, Ankara
G. Ewy, Tucson, Ariz.
M.D. Ezekowitz, Wynnewood, Pa.
R. Ferrari, Ferrara
G. Filippatos, Athens
G.I. Fishman, New York, N.Y.
K. Fox, London
G.S. Francis, Minneapolis, Minn.
V. Fuster, New York, N.Y.
B.J. Gersh, Rochester, Minn.
W. Gersony, New York, N.Y.
J.P. Gold, Toledo, Ohio
M.E. Goldman, New York, N.Y.
P.J. Goldschmidt, Miami, Fla.
T.H. Haghfelt, Odense
J.L. Halperin, New York, N.Y.
Z.-X. He, Beijing
E.M. Herrold, Brooklyn, N.Y.
G. Heusch, Essen

(Continued on next page)
Submission

‘Cardiology’ publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy. Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be clear that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Main Sections

1. Original Research
2. Original Research – Clinical Trial Design
3. Review
4. Turning Basic Research into Clinical Success
5. Transaction
6. Novel Insights from Clinical Experience (formerly Case Reports)
7. Short Communications
8. Commentary
9. Case Reports

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Cardiology’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest in Cardiovascular Publications

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism

Authors should not appropriate the ideas, language or other elements of the work of others without providing appropriate attribution (i.e., ‘plagiarism’). Plagiarism includes, but is not limited to, verbatim copying without quotation marks, close paraphrasing or summarization of sentences or narrative passages without citing source, and duplication of figures, graphs, images or data without acknowledgement of their origins. Authors also should not submit a previously published manuscript or a section of a previously published manuscript, even when re-titled, otherwise re-worded or augmented, without clearly identifying its relation to the author's earlier work (duplicate publication or 'self-plagiarism'). For additional guidance, see Roig M.; Plagiarism and self-plagiarism: What every author should know. Biochemia Medica 2010;20:295–300.

Arrangement

Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as a running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

For submissions to Main Sections 1, 2 and 3

Original Research, Original Research – Clinical Trial Design, and Review Papers

Abstract: The abstract is an essential and most read part of the paper. It should be printed on a separate page, up to 200 words, factual, free of abbreviations (except as specifically defined within the abstract text at first use) and should be structured as follows:

Objective: Should describe the purpose of the study and the problem addressed, should include at least one sentence providing the rationale or justification for the study.

Methods: Should explain how the study was performed (samples and/or population, procedures, analytical methods).

Results: Should describe the main findings with specific data and their statistical significance, if possible.

Conclusions: Should contain a succinct interpretation of the inferences to be drawn from results.

Guidelines for Authors

www.karger.com/crd

If you have any problems with submission, please contact:

S. Karger AG
Editorial Office ‘Cardiology’
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1357
Fax +41 61 306 1434
E-Mail crd@karger.ch

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Contact:
Fax +41 61 306 1234
E-Mail karger@karger.ch
www.karger.com

© 2012 S. Karger AG, Basel

The Guidelines for Authors are available at:

www.karger.com/crd_Guidelines
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at http://www.karger.com/crd/).

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journals according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theocharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modifications or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice

With this option the author can choose to make his article freely available online against a one-time fee of CHF 3000.–. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copypasting and design improvements as well as citation links.

Page Charges

There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
General Information

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

**Personal subscription:**
- Print or Online: CHF 597.–
- USD 478.–
- EUR 478.–
- Print and handling: USD 580.00
- EUR 522.00

**Print-On-Online combined:**
- CHF 741.–
- EUR 592.–
- USD 721.00

**Institutional subscription:**
- Print or Online: CHF 3981.–
- EUR 3186.–
- USD 3864.00
- Postage and handling: USD 141.00
- EUR 112.80

**Print-On-Online combined:**
- CHF 4380.–
- EUR 3504.–
- USD 4251.00

**Airmail surcharge:** USD 96.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.ch.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923 (USA). A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

Subscription Orders: Orders can be placed at agencies, bookstores, directly with the Publisher or further Karger offices or representatives:

**S. Karger AG**
Medical and Scientific Publishers
P.O. Box
CH–4009 Basel
Switzerland
(for courier services only: Allschwilerstrasse 10
CH–4055 Basel)
t: +41 61 306 11 11
f: +41 61 306 12 34
e: karger@karger.ch
w: www.karger.com

**S. Karger GmbH**
Postfach
79095 Freiburg
Deutschland
(Hausadresse: Wilhelmstrasse 20A, 79098 Freiburg)
t: +49 761 45 20 70
f: +49 761 45 20 714
e: informations@karger.de
w: www.karger.de

**S. Karger Japan, Inc.**
Shiba Daion, Asahi Bldg. 2F
1-2-23 Shiba Daion
Minato-ku
Tokyo 105-0012
Japan
t: +81 3 6435 6242
f: +81 3 6435 6244
e: publisher@karger.jp
w: www.karger.jp

**Japan**
Librairie Médicale Sciences Sarl
36, bd de Laturu-Maubourg
75007 Paris
France
t: +33 (0) 1 45 51 42 58
f: +33 (0) 1 45 56 07 80
e: librairie@medi-sciences.fr
w: www.medi-sciences.fr

**Gulf Council Countries, Iran, Middle East, North Africa, Turkey**
KaSha
134 Queen Rania Al Abdullah Street
Jordan Trade Center Bldg., 3rd Floor
P.O. Box 2376
Amman 11953
Jordan
t: +962 6 515 3476
f: +962 6 515 3472
e: info@kasha.cc
w: www.KaShaonline.com

**South East Asia, China and Taiwan**
Karger Regional Office (Malaysia)
CEO Suite Kuala Lumpur
Quill 7, 27th Floor
Jalan Stesen Sentral 5
KL Sentral
Kuala Lumpur 50470
Malaysia
t: +60 3 2776 6803
f: +60 3 2776 6999
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

Karger China
10th Floor, Twin Towers (East)
B12 Jangguomenwai Avenue
Beijing 100022
China
t: +86 10 5123 5033
f: +86 10 5123 5122
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

**Karger India**
PLOT NO. 17, YUSUF SARAI MARKET
NEW DELHI 110 016
INDIA
t: +91 11 46029 633
f: +91 11 46029 634
e: medsci.india@gmail.com

Change of Address: Both old and new address should be sent to the subscription source.
The European Society of Cardiology presents the world’s premier conference on the science, management and prevention of cardiovascular disease.

This year’s spotlight is “From bench to practice”

Advance programme now available online:
www.escardio.org/ESC2012programme

400+ scientific sessions to:
- Experience the new organisation in themed villages*
- Exchange with leading experts during interactive sessions
- Discover the very latest clinical trial results

*Find out more about the villages at www.escardio.org

Win a free congress registration
(or visit www.escardio.org/esc2012-prize) to enter the prize draw* for a free registration for ESC Congress 2012 in Munich

*Rules and regulations available at www.escardio.org

2011 Key figures:
- 5 days of scientific sessions
- 32,000+ healthcare professionals from 150+ countries
- 10,800+ abstracts submitted
- 4200+ selected abstracts
- 70 industry sponsored sessions
- 200 exhibiting companies
- + unique & unlimited opportunities to network!

Register Now!
Online at www.escardio.org
31 July 2012: Advance registration deadline
Contents

See the journal website for contents
The journal of 'CardioRenal Medicine' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues. Attention is paid to the fact that some disorders associated with the metabolic syndrome cluster with albuminuria and chronic kidney disease. Moreover, certain metabolic abnormalities of the heart promote impaired coronary artery endothelial function, diastolic dysfunction and ischemic reconditioning. Another point of focus is the role of the obesity epidemic in promoting the increasing incidence of kidney disease and diastolic heart failure in industrialized countries, and the prevailing problems of insufficient exercise and excessive consumption of cheap, unwholesome food in promotion of the cardiorenal metabolic syndrome in both adults and children.

'CardioRenal Medicine' addresses a multidisciplinary audience consisting of nephrologists, cardiologists, nutritionists, endocrinologists, physiologists and general internists.

Selected contributions
The Heart and the Kidneys: Partners in Disease? Sowers, J.R. (Columbia, Mo.)
Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats: Indborg, K.A. (Tucson, Ariz.); Jacob, S. (Villingen-Schwenningen); Henriksen, E.J. (Tucson, Ariz.)
Interaction between Adiponectin and Aldosterone: Flynn, C.; Bakris, G.L. (Chicago, Ill.)
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney: Pulakat, L.; DeMarco, V.G.; Whaley-Connell, A.; Sowers, J.R. (Columbia, Mo.)
An Emerging Role for Understanding Orthostatic Hypertension in the Cardiorenal Syndrome: Buddinesi, J.P.; Chauhan, L.; Ahsan, S.T.; Whaley-Connell, A. (Columbia Mo.)

More information at www.karger.com/crm
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation
Obstructive Sleep Apnea in Adults
Relationship with Cardiovascular and Metabolic Disorders

Contents
- Obstructive Sleep Apnea in Adults: Epidemiology, Clinical Presentation, and Treatment Options
- Inflammation, Oxidative Stress, and Procoagulant and Thrombotic Activity in Adults with Obstructive Sleep Apnea
- Metabolic Disorders Associated with Obstructive Sleep Apnea in Adults
- Endothelial Dysfunction in Adults with Obstructive Sleep Apnea
- Hemodynamic and Autonomic Changes in Adults with Obstructive Sleep Apnea
- Cardiovascular Disorders Associated with Obstructive Sleep Apnea

This book aims to provide a comprehensive and clear review of the current knowledge of the relationship between obstructive sleep apnea (OSA) and cardiovascular and metabolic diseases, a subject of concern to a wide range of specialists and general practitioners. Separate chapters describe: the definition, symptoms and sequelae of OSA, and the diagnostic strategies and treatment options for adults with OSA according to the American Academy of Sleep Medicine; pathogenic mechanisms, by which OSA may contribute to the development and progression of cardiovascular and metabolic disorders, including inflammation, oxidative stress and thrombosis; links between OSA and obesity, alterations in glucose metabolism, metabolic syndrome and liver injury; relationships between OSA, endothelial dysfunction, autonomic dysfunction and cardiovascular disorders, and the results of studies investigating the effect of treatment for OSA on the concomitant cardiovascular disease.

Each chapter summarizes the essential information and is illustrated by tables and figures, which will aid the readers in their understanding of the complex systemic interactions involved in this disease.

Reviewed by internationally recognized experts, this publication will be of benefit to clinicians and scientists in the fields of pulmonology, cardiology, endocrinology and neurology as well as to sleep specialists and general practitioners.
Modern medicine is now in a position to make advanced prognoses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take. In this publication, renowned experts in their fields discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of an afterlife.

This publication aims to bridge the different fields dealing with this area by addressing the challenges faced and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists.

Contents

Introduction: Pfl eiderer, G.; Battegay, M.; Lindpaintner, K.

Medical Perspectives
- Evolving Therapy and Prognosis in HIV – How Knowing One’s Medical Fate in Advance Can Change Dramatically: Battegay, M.
- Related to Human Cognition: Is Personalization Feasible and Desirable?: Papassotiropoulos, A.

Ethical and Juridical Perspectives
- Ethical Decision-Making on Genetic Diagnosis Facing the Challenges of Knowing One’s Medical Fate in Advance: Brahier, G.
- Predictive Medicine – Changes in Our View of Ourselves and Others: Bimhaches, D.
- Current Challenges for the Law: Disclosure Dilemmas in Predictive Medicine: Dörr, B.S.

Religious Perspectives
- Fate and Judaism – Philosophical and Clinical Aspects: Gesundheit, B.
- Karma, Contingency, and the ‘Point of No Return’: Predictive Medicine and Buddhist Perspectives: Schlieter, J.

Author Index
Subject Index

www.karger.com/medical-fate
An excellent overview of recent advances in diagnosis, classification and treatment

Pulmonary Vascular Disorders

Editors
Marc Humbert
Rogerio Souza
Gérald Simonneau

Contents
Foreword
Preface

Updated Clinical Classification of Pulmonary Hypertension: Montani, D.; Simonneau, G.
Pathology of Pulmonary Arterial Hypertension: Dorfmüller, P.
Exercise Testing in Pulmonary Arterial Hypertension: Provencher, S.; Mainguy, V.
Noninvasive Exploration of the Pulmonary Circulation and the Right Heart: Vonk Noordegraaf, A.; Peacock, A.; Naeije, R.
Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension: Girerd, B.; Montani, D.; Yaici, A.; Eyrès, M.; Coulet, F.; Soubrier, F.; Humbert, M.
Drug- and Toxin-Induced Pulmonary Arterial Hypertension: Price, L.; Bouillon, K.; Wort, S.J.;

Humbert, M.
Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries: Jiang, X.; Humbert, M.; Jing, Z.-C.
Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders: Le Pavec, J.; Hassoun, P.M.
Pulmonary Arterial Hypertension and HIV and Other Viral Infections: Degano, B.; Valmary, S.; Sitbon, O.; Humbert, M.
Portopulmonary Hypertension and Hepatopulmonary Syndrome: Savale, L.; Hervé, P.; Sitbon, O.
Pulmonary Hypertension in Congenital Heart Disease: Tissot, C.; Béchetti, M.
Pulmonary Hypertension in Sickle Cell Disease: Parent, F.; Savale, L.; Maître, B.; Simonneau, G.
Pulmonary Venous-Obstructive Disease: Montani, D.; Huertas, A.; Dormüller, P.; Humbert, M.
Pulmonary Hypertension and Left Heart Disease: Adir, Y.; Galili, N.
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Weitzenblum, E.;

Chauwat, A.; Canuet, M.; Ducloné, A.; Kessler, R.
Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases: Nunes, H.; Uzunhan, Y.; Gille, T.; Daumiat, G.; Braunier, M.; Kambouchner, M.; Valeyre, D.
High-Altitude Pulmonary Hypertension: Di, R.-M.; Jing, Z.-C.
Acute Pulmonary Venous Thromboembolic Disease: Sanchez, Q.; Meyer, G.
Anticoagulation for Venous Thromboembolism in the Modern Management Era: Le Gal, G.; Leroyer, C.; Mottier, D.
Chronic Thromboembolic Pulmonary Hypertension: Lang, I.M.; Jais, X.
Medical Treatment of Pulmonary Arterial Hypertension: O’Callaghan, D.S.; Gaine, S.P.
Lung Transplantation and Role for Novel Extracorporeal Support in Pulmonary Hypertension: Hoeper, M.M.
Atrial Septostomy: Vachiéry, J.-L.
Pulmonary Vascular Disorders in Hereditary Hemorrhagic Telangiectasia: Cottin, V.; Khoura, C.; Dupuis-Girod, S.; Cordier, J.-F.
Future Perspectives in Pulmonary Arterial Hypertension: Rubin, L.J.

Author and Subject Index